CHINA PHARMA HOLDINGS, INC. Inventory Write-down
CHINA PHARMA HOLDINGS, INC. (CPHI) reported Inventory Write-down of $549.22 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-04-01.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-08-14
- CHINA PHARMA HOLDINGS, INC. inventory write-down for the quarter ending 2025-12-31 was $42.34K.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for the quarter ending 2025-09-30 was $83.95K, a 59.74% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for the quarter ending 2025-06-30 was $209.55K, a 26.52% decline year-over-year.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for the quarter ending 2025-03-31 was $213.38K, a 69.00% increase year-over-year.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for fiscal 2025 was $549.22K, a 21.85% increase from fiscal 2024.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for fiscal 2024 was $450.74K.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for fiscal 2023 was -$7.97K.
- CHINA PHARMA HOLDINGS, INC. inventory write-down for fiscal 2019 was $253.47K, a 73.44% decline from fiscal 2018.
| Period end | Inventory Write-down 3 month | Inventory Write-down 6 month | Inventory Write-down 9 month | Inventory Write-down 12 month |
|---|---|---|---|---|
| 2025-12-31 | $42.34K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $126.29K derived: sum of 2 quarters · filed 2026-04-01 | $335.84K derived: sum of 3 quarters · filed 2026-08-14 | $549.22K 10-K · filed 2026-04-01 |
| 2025-09-30 | $83.95K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $293.50K derived: sum of 2 quarters · filed 2026-08-14 | $506.88K 10-Q · filed 2025-11-12 | $493.63K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | $209.55K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $422.93K 10-Q · filed 2026-08-14 | $409.69K derived: sum of 3 quarters · filed 2026-08-14 | $462.24K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | $213.38K 10-Q · filed 2025-05-14 | $200.13K derived: sum of 2 quarters · filed 2026-04-01 | $252.69K derived: sum of 3 quarters · filed 2026-04-01 | $537.86K derived: sum of 4 quarters · filed 2026-04-01 |
| 2024-12-31 | -$13.25K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-01 | $39.31K derived: sum of 2 quarters · filed 2026-04-01 | $324.48K derived: sum of 3 quarters · filed 2026-04-01 | $450.74K 10-K · filed 2026-04-01 |
| 2024-09-30 | $52.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $337.73K derived: sum of 2 quarters · filed 2025-11-12 | $463.98K 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $285.17K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | $411.43K 10-Q · filed 2025-08-14 | ||
| 2024-03-31 | $126.26K 10-Q · filed 2025-05-14 | |||
| 2023-12-31 | -$7.97K 10-K · filed 2025-03-31 | |||
| 2023-06-30 | $24.26K 10-Q · filed 2024-08-14 | |||
| 2022-03-31 | $10.16K 10-Q · filed 2022-05-12 | |||
| 2021-09-30 | $26.78K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $94.24K derived: sum of 2 quarters · filed 2022-11-14 | $148.39K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $67.46K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $121.60K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $54.15K 10-Q · filed 2022-05-12 | |||
| 2019-12-31 | $165.92K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-26 | $141.93K derived: sum of 2 quarters · filed 2021-03-26 | $253.47K 10-K · filed 2021-03-26 | |
| 2019-09-30 | -$23.99K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-13 | $87.54K 10-Q · filed 2020-11-13 | ||
| 2019-06-30 | $111.53K 10-Q · filed 2020-08-13 | |||
| 2018-12-31 | $954.31K 10-K · filed 2020-03-30 | |||
| 2018-06-30 | $148.56K 10-Q · filed 2019-08-14 | |||
| 2017-12-31 | $118.00K 10-K · filed 2019-03-28 | |||
| 2016-12-31 | -$200.04K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | -$120.32K derived: sum of 2 quarters · filed 2017-03-31 | $71.79K derived: sum of 3 quarters · filed 2017-03-31 | $0.00 10-K · filed 2017-03-31 |
| 2016-09-30 | $79.73K 10-Q · filed 2016-11-14 | $271.83K derived: sum of 2 quarters · filed 2016-11-14 | $200.04K 10-Q · filed 2016-11-14 | $1.45M derived: sum of 4 quarters · filed 2017-03-31 |
| 2016-06-30 | $192.10K 10-Q · filed 2016-08-11 | $120.32K 10-Q · filed 2016-08-11 | $1.37M derived: sum of 3 quarters · filed 2017-03-31 | $1.81M derived: sum of 4 quarters · filed 2017-03-31 |
| 2016-03-31 | -$71.79K 10-Q · filed 2016-05-16 | $1.18M derived: sum of 2 quarters · filed 2017-03-31 | $1.62M derived: sum of 3 quarters · filed 2017-03-31 | $2.84M derived: sum of 4 quarters · filed 2017-03-31 |
| 2015-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-31 | $1.69M derived: sum of 2 quarters · filed 2017-03-31 | $2.91M derived: sum of 3 quarters · filed 2017-03-31 | $3.11M 10-K · filed 2017-03-31 |
| 2015-09-30 | $436.67K 10-Q · filed 2016-11-14 | $1.65M derived: sum of 2 quarters · filed 2016-11-14 | $1.86M 10-Q · filed 2016-11-14 | $4.11M derived: sum of 4 quarters · filed 2016-11-14 |
| 2015-06-30 | $1.22M 10-Q · filed 2016-08-11 | $1.42M 10-Q · filed 2016-08-11 | $3.67M derived: sum of 3 quarters · filed 2016-08-11 | $3.67M derived: sum of 4 quarters · filed 2016-08-11 |
| 2015-03-31 | $201.10K 10-Q · filed 2016-05-16 | $2.45M derived: sum of 2 quarters · filed 2016-05-16 | $2.45M derived: sum of 3 quarters · filed 2016-05-16 | $2.45M derived: sum of 4 quarters · filed 2016-05-16 |
| 2014-12-31 | $2.25M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-30 | $2.25M derived: sum of 2 quarters · filed 2016-03-30 | $2.25M derived: sum of 3 quarters · filed 2016-03-30 | $2.25M 10-K · filed 2016-03-30 |
| 2014-09-30 | $0.00 10-Q · filed 2015-12-28 | $0.00 derived: sum of 2 quarters · filed 2015-12-28 | $0.00 10-Q · filed 2015-12-28 | $6.15M derived: sum of 4 quarters · filed 2015-12-28 |
| 2014-06-30 | $0.00 10-Q · filed 2015-12-28 | $0.00 10-Q · filed 2015-12-28 | $6.15M derived: sum of 3 quarters · filed 2015-12-28 | $6.16M derived: sum of 4 quarters · filed 2015-12-28 |
| 2014-03-31 | $0.00 10-Q · filed 2014-05-15 | $6.15M derived: sum of 2 quarters · filed 2015-12-28 | $6.16M derived: sum of 3 quarters · filed 2015-12-28 | $6.19M derived: sum of 4 quarters · filed 2015-12-28 |
| 2013-12-31 | $6.15M derived: 10-K 12 month − 10-Q 9 month · filed 2015-12-28 | $6.16M derived: sum of 2 quarters · filed 2015-12-28 | $6.19M derived: sum of 3 quarters · filed 2015-12-28 | $9.88M 10-K · filed 2015-12-28 |
| 2013-09-30 | $15.75K 10-Q · filed 2014-11-14 | $42.92K derived: sum of 2 quarters · filed 2014-11-14 | $3.74M 10-Q · filed 2014-11-14 | $5.51M derived: sum of 4 quarters · filed 2014-11-14 |
| 2013-06-30 | $27.18K 10-Q · filed 2014-08-14 | $3.72M 10-Q · filed 2014-08-14 | $5.49M derived: sum of 3 quarters · filed 2014-08-14 | $5.49M derived: sum of 4 quarters · filed 2014-08-14 |
| 2013-03-31 | $3.69M 10-Q · filed 2014-05-15 | $5.46M derived: sum of 2 quarters · filed 2014-05-15 | $5.46M derived: sum of 3 quarters · filed 2014-05-15 | $5.46M derived: sum of 4 quarters · filed 2014-05-15 |
| 2012-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-20 | $1.77M derived: sum of 2 quarters · filed 2014-03-20 | $1.77M derived: sum of 3 quarters · filed 2014-03-20 | $1.77M 10-K · filed 2014-03-20 |
| 2012-09-30 | $0.00 10-Q · filed 2013-11-14 | $0.00 derived: sum of 2 quarters · filed 2013-11-14 | $0.00 10-Q · filed 2013-11-14 | |
| 2012-06-30 | $0.00 10-Q · filed 2013-08-14 | $0.00 10-Q · filed 2013-08-14 | ||
| 2012-03-31 | $0.00 10-Q · filed 2013-05-14 | |||
| 2011-12-31 | $0.00 10-K · filed 2013-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |